September 27, 2022
Janssen Pharmaceutical said on September 26 that it has obtained Japanese regulatory approval for its CAR-T cell therapy Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of relapsed or refractory multiple myeloma (MM). Carvykti will be only used for patients 1)...read more